TTrialPathMatch Me to Trials
← Back to trials
RecruitingHuman Immunodeficiency VirusEnd Stage Renal Disease

Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. All such transplants must occur under an institutional review board (IRB) approved research protocol that is compliant with federal regulations governing human subjects research. This is an investigator-initiated, observational prospective study of solid organ transplantation utilizing HIV-positive donors in HIV positive recipients. Stable HIV-infected adults in need of a solid organ transplant (kidney) who meet standard and study specified HIV criteria for organ transplantation will be offered enrollment in the study. Deceased donors (kidney) and living donors (kidney) will be utilized in this protocol. The goal of this research is to increase knowledge about the safety, efficacy, and effectiveness of solid organ transplantation (SOT) utilizing HIV-positive donors in HIV-positive recipients.

Sponsor: Tulane University

You may qualify if…

  • ✓ Participant meets standard listing criteria for transplant.
  • ✓ Greater than or equal to 18 years of age.
  • ✓ Participant has documented HIV infection using an FDA-licensed, approved, or cleared test device(s).
  • ✓ CD4+ T-cell count ≥200/μL within 16 weeks prior to transplant; any patient with history of Opportunistic Infections must have a CD4 positive T-cell count ≥200/uL.
  • ✓ HIV RNA less than 50 copies/mL and on a stable antiretroviral regimen.
  • ✓ No evidence of active opportunistic complications of HIV infection.
  • ✓ On a stable antiretroviral regimen. Participants unable to tolerate ART due to organ failure may still be considered eligible if the study team is confident there will be a safe, tolerable, and effective antiretroviral regimen once organ function is restored after transplantation.
  • ✓ No history of primary CNS lymphoma or progressive PML

You may not qualify if…

  • ✕ Participant has concomitant conditions that, in the judgment of the investigators, would preclude transplantation or immunosuppression.
  • ✕ Less than 18 years of age.
  • ✕ Requires multi-organ transplantation.
  • ✕ Participant is pregnant or breastfeeding.
  • ✕ Participant has a history of progressive multifocal leukoencephalopathy (PML), chronic intestinal cryptosporidiosis of \> 1 month duration, or primary CNS lymphoma.
  • ✕ Participant has a history of any neoplasm except for the following: resolved Kaposi's sarcoma, in situ anogenital carcinoma, adequately treated basal or squamous cell carcinoma of the skin, solid tumors (except primary CNS lymphoma) treated with curative therapy and disease free for more than 5 years. History of renal cell carcinoma requires disease-free state for 2 years. History of leukemia and disease free duration will be per site policy.
  • ✕ Participants who are unable or unwilling to provide informed consent.
  • ✕ Donor Criteria Deceased Donor Criteria

Where it's recruiting

Louisiana

Metairie

Source: ClinicalTrials.gov · NCT05159466 · last updated 2025-10-02